tradmap

DSGN Earnings Design Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $1 $0 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$70M -$35M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $1 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$20M -$10M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.612026-08-0310-Q
Q1 20262026-03-31-0.292026-04-2810-Q
FY 20252025-12-31-1.222026-03-0910-K
Q3 20252025-09-30-0.952025-11-0510-Q
Q2 20262025-06-30-0.652026-08-0310-Q
Q1 20262025-03-31-0.312026-04-2810-Q
FY 20252024-12-31-0.882026-03-0910-K
Q3 20252024-09-30-0.642025-11-0510-Q
Q2 20252024-06-30-0.412025-08-0710-Q
Q1 20252024-03-31-0.202025-05-0710-Q
FY 20242023-12-31-1.192025-03-1010-K
Q3 20242023-09-30-0.982024-11-0710-Q
Q2 20242023-06-30-0.702024-08-0510-Q
Q1 20242023-03-31-0.352024-05-0810-Q
FY 20232022-12-31-1.142024-03-1910-K
Q3 20232022-09-30-0.832023-11-1310-Q
Q2 20232022-06-30-0.512023-08-1410-Q
Q1 20232022-03-31-0.242023-05-0910-Q
FY 20222021-12-31-0.772023-03-1410-K
Q3 20222021-09-30-0.572022-11-0310-Q
Q2 20222021-06-30-0.362022-08-0810-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.